Potent 5-Cyano-6-phenyl-pyrimidin-Based Derivatives Targeting DCN1-UBE2M Interaction.

Wenjuan Zhou, Liying Ma, Lina Ding, Qian Guo, Zhangxu He, Jing Yang, Hui Qiao, Lingyu Li, Jie Yang, Shimin Yu, Lili Zhao, Shaomeng Wang, Hong-Min Liu, Zhenhe Suo, Wen Zhao
Author Information
  1. Wenjuan Zhou: State Key Laboratory of Esophageal Cancer Prevention and Treatment; Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education of China; School of Pharmaceutical Sciences , Zhengzhou University , 100 Kexue Avenue , Zhengzhou , Henan 450001 , China. ORCID
  2. Liying Ma: State Key Laboratory of Esophageal Cancer Prevention and Treatment; Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education of China; School of Pharmaceutical Sciences , Zhengzhou University , 100 Kexue Avenue , Zhengzhou , Henan 450001 , China.
  3. Lina Ding: State Key Laboratory of Esophageal Cancer Prevention and Treatment; Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education of China; School of Pharmaceutical Sciences , Zhengzhou University , 100 Kexue Avenue , Zhengzhou , Henan 450001 , China.
  4. Qian Guo: State Key Laboratory of Esophageal Cancer Prevention and Treatment; Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education of China; School of Pharmaceutical Sciences , Zhengzhou University , 100 Kexue Avenue , Zhengzhou , Henan 450001 , China.
  5. Zhangxu He: State Key Laboratory of Esophageal Cancer Prevention and Treatment; Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education of China; School of Pharmaceutical Sciences , Zhengzhou University , 100 Kexue Avenue , Zhengzhou , Henan 450001 , China.
  6. Jing Yang: State Key Laboratory of Esophageal Cancer Prevention and Treatment; Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education of China; School of Pharmaceutical Sciences , Zhengzhou University , 100 Kexue Avenue , Zhengzhou , Henan 450001 , China.
  7. Hui Qiao: State Key Laboratory of Esophageal Cancer Prevention and Treatment; Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education of China; School of Pharmaceutical Sciences , Zhengzhou University , 100 Kexue Avenue , Zhengzhou , Henan 450001 , China.
  8. Lingyu Li: State Key Laboratory of Esophageal Cancer Prevention and Treatment; Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education of China; School of Pharmaceutical Sciences , Zhengzhou University , 100 Kexue Avenue , Zhengzhou , Henan 450001 , China.
  9. Jie Yang: State Key Laboratory of Esophageal Cancer Prevention and Treatment; Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education of China; School of Pharmaceutical Sciences , Zhengzhou University , 100 Kexue Avenue , Zhengzhou , Henan 450001 , China.
  10. Shimin Yu: State Key Laboratory of Esophageal Cancer Prevention and Treatment; Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education of China; School of Pharmaceutical Sciences , Zhengzhou University , 100 Kexue Avenue , Zhengzhou , Henan 450001 , China.
  11. Lili Zhao: State Key Laboratory of Esophageal Cancer Prevention and Treatment; Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education of China; School of Pharmaceutical Sciences , Zhengzhou University , 100 Kexue Avenue , Zhengzhou , Henan 450001 , China.
  12. Shaomeng Wang: State Key Laboratory of Esophageal Cancer Prevention and Treatment; Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education of China; School of Pharmaceutical Sciences , Zhengzhou University , 100 Kexue Avenue , Zhengzhou , Henan 450001 , China. ORCID
  13. Hong-Min Liu: State Key Laboratory of Esophageal Cancer Prevention and Treatment; Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education of China; School of Pharmaceutical Sciences , Zhengzhou University , 100 Kexue Avenue , Zhengzhou , Henan 450001 , China. ORCID
  14. Zhenhe Suo: Department of Pathology , Oslo University Hospital; Faculty of Medicine, University of Oslo , Oslo 0379 , Norway.
  15. Wen Zhao: State Key Laboratory of Esophageal Cancer Prevention and Treatment; Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education of China; School of Pharmaceutical Sciences , Zhengzhou University , 100 Kexue Avenue , Zhengzhou , Henan 450001 , China. ORCID

Abstract

Neddylation of the Cullin-RING E3 ligases (CRLs) regulates the homeostasis of approximately 20% of cellular proteins. Defective in cullin neddylation 1 (DCN1), as a co-E3 ligase, interacts with UBE2M to enhance the activation of CRLs, and this interaction is emerging as a therapeutic target for human diseases. Here, we present a series of pyrimidin-based small molecular inhibitors targeting DCN1-UBE2M interaction. After finding a novel inhibitor DC-1 with IC = 1.2 μM, we performed a series of chemical optimizations, which finally led to the discovery of a potent thiazole containing 5-cyano-6-phenylpyrimidin-based inhibitor DC-2 (IC = 15 nM). Next, using protein and cellular thermal shift assays, coimmunoprecipitation, molecular docking, and site-specific mutation experiments, we further proved that DC-2 specifically inhibited the interaction of UBE2M and DCN1 at molecule and cellular levels, resulting in the decrease of cullin3 neddylation and accumulation of its substrate, NRF2. Our findings indicate that DC-2 may serve as a novel lead compound for specific derivatives targeting DCN1-UBE2M interaction.

MeSH Term

Humans
Intracellular Signaling Peptides and Proteins
Molecular Docking Simulation
Protein Conformation
Pyrimidines
Ubiquitin-Conjugating Enzymes

Chemicals

DCUN1D1 protein, human
Intracellular Signaling Peptides and Proteins
Pyrimidines
Ubiquitin-Conjugating Enzymes
UBE2M protein, human
pyrimidine

Word Cloud

Created with Highcharts 10.0.0interactioncellularDCN1-UBE2MDC-2CRLsneddylation1DCN1UBE2MseriesmoleculartargetingnovelinhibitorIC=NeddylationCullin-RINGE3ligasesregulateshomeostasisapproximately20%proteinsDefectivecullinco-E3ligaseinteractsenhanceactivationemergingtherapeutictargethumandiseasespresentpyrimidin-basedsmallinhibitorsfindingDC-12μMperformedchemicaloptimizationsfinallyleddiscoverypotentthiazolecontaining5-cyano-6-phenylpyrimidin-based15nMNextusingproteinthermalshiftassayscoimmunoprecipitationdockingsite-specificmutationexperimentsprovedspecificallyinhibitedmoleculelevelsresultingdecreasecullin3accumulationsubstrateNRF2findingsindicatemayserveleadcompoundspecificderivativesPotent5-Cyano-6-phenyl-pyrimidin-BasedDerivativesTargetingInteraction

Similar Articles

Cited By